Optimi Health Announces C$3.27 Million Private Placement with Strategic Investment from Lululemon Founder Chip Wilson

Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) is a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP-grade psilocybin, synthetic psychedelic substances and functional mushrooms for the health and wellness markets. 

On October 11, Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) announced that it has closed a non-brokered private placement of 5,692,308 units at a price of $0.325 per unit for gross proceeds of $1.85 million with Chip Wilson. Chip Wilson was the founder of Lululemon and is a well known Global wellness supporter and philanthropist. 

“Our participation in the placement speaks to our belief that the company can achieve its plan to be a world leader in psychedelic product development and global distribution,” said Wilson.

Each Unit consists of one common share of Optimi (CSE:OPTI) (OTCQX:OPTHF) and one-half of one common share purchase warrant. Each Warrant is exercisable at $0.50 for a period of two years from the date of issuance. 

Optimi (CSE:OPTI) (OTCQX:OPTHF) intends to use the proceeds to support its psychedelic product commercialization efforts in preparation for regulating in Oregon and the recently announced Alberta rollout, as well as  ongoing psilocybin and MDMA research and the Company’s clinical trial initiatives, in-house drug development,  and general working capital.

Upon closing the transaction, Chip Wilson’ will acquire 5,692,308 shares of Optimi Health (CSE:OPTI) (OTCQX:OPTHF) at C$0.32 per share, with additional shares available through warrants priced at C$0.50, which are exercisable for up to 24 months, and would increase Wilson’s position to 9.5% of all outstanding shares fully diluted. The financing is subject to customary closing conditions regulated by the Canadian Securities Exchange.

Chip Wilson, who founded Lululemon, is also on the Advisory Board of Optimi Health (CSE:OPTI) (OTCQX:OPTHF).

 “It is important to demonstrate both to our existing shareholders and the market at large that Optimi’s leadership is taking an active role in raising smart capital,” said Optimi Health (CSE:OPTI) (OTCQX:OPTHF) CEO, Bill Ciprick. “When looking at a variety of potential funding options to lead this round of financing, apart from ensuring the terms of the financing were highly competitive, expanding its relationship with Chip through this investment was the preferred scenario given Chip’s familiarity with the operational business, his ongoing support to Optimi (CSE:OPTI) (OTCQX:OPTHF) in an advisory capacity, and understanding of management and the Board’s track record and commitment to achieving its near and long-term corporate milestones.”

 “This sends the right message at the right time to investors paying close attention to the psychedelics market. When an investor like Chip Wilson offers to increase his position and back the future of Optimi (CSE:OPTI) (OTCQX:OPTHF), you find a way to get a deal done,” said Optimi (CSE:OPTI) (OTCQX:OPTHF) co-founder, director and CMO, Dane Stevens. “Optimi (CSE:OPTI) (OTCQX:OPTHF) would not exist without the vision and commitment of JJ and Chip Wilson, the Safarik family, and the shared belief that the work we are doing today will improve the health of so many in need for many years to come. With this strategic raise, we are building trust with shareholders and operations team alike, and demonstrating that the Company’s Founders and leadership team are committed to the long-term success and growth of Optimi (CSE:OPTI) (OTCQX:OPTHF).”

The Wilson family also recently made a $100 million donation, the largest in history, to the BC Parks Foundation and established Solve FSHD, a foundation to research into a cure for facioscapulohumeral muscular dystrophy, with an additional $100 million. These were facilitated by the family’s private foundation, the Wilson 5 Foundation.

Optimi Health (CSE:OPTI) (OTCQX:OPTHF) and ATMA Journey Centers File Phase I Natural Psilocybin and MDMA Clinical Trial Application with Health Canada

On September 22, Optimi Health (CSE:OPTI) (OTCQX:OPTHF) announced that the company, in collaboration with ATMA Journey Centers, will proceed with a Phase I clinical trial application (CTA) that will demonstrate the safety of Optimi‘s (CSE:OPTI) (OTCQX:OPTHF) natural psilocybin biomass and 3,4-methylenedioxy-methamphetamine (MDMA) in healthy patients.

It would be the first investigation allowed by Health Canada to assess the safety and other markers, such as the mystical experience questionnaire, in healthy MDMA users.

According to Optimi (CSE:OPTI) (OTCQX:OPTHF) CEO Bill Ciprick, the clinical investigation’s goal is to collect data for Optimi‘s (CSE:OPTI) (OTCQX:OPTHF) unique formulation using natural EU-GMP psilocybin and MDMA, such as blood pressure, temperature, heart rate, and ECG measures. Optimi‘s (CSE:OPTI) (OTCQX:OPTHF) 20,000-square-foot plant in Princeton, B.C. manufactures and tests these products in-house. According to Ciprick, clinical validation of their solutions for healthy individuals brings them one step closer to commercialization.

According to Optimi‘s (CSE:OPTI) (OTCQX:OPTHF) commercialization plan, the company aims to be a global leader in meeting therapist demand for natural EU-GMP psilocybin and MDMA.

For more information on Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF), please visit this link.